NCT06847321View on ClinicalTrials.gov

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2028

Conditions
Alzheimer DiseaseAlzheimer Disease Due to P. Gingivalis
Interventions
DRUG

LHP588

25 mg

DRUG

LHP588

50 mg

DRUG

Placebo Drug

Placebo

Trial Locations (1)

98007

RECRUITING

Northwest Clinical Research Center, Bellevue

Sponsors
All Listed Sponsors
lead

Lighthouse Pharmaceuticals, Inc.

INDUSTRY